Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease. (Q40180170)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Xiaoyu Zhang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Henrik S Olsen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Edward So

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hua Zhou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Erin Burch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Emmanuel Y Mérigeon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David S Block

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Scott E Strome

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

22 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

published in

Journal of Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

1165-1176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26695368%20AND%20SRC:MED&resulttype=core&format=json

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

The effect of desensitization protocols on human splenic B-cell populations in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Rituximab and intravenous immune globulin for desensitization during renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)?

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Aggregated IgG inhibits the differentiation of human fibrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis).

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Human IgG2 can form covalent dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Human IgG2 antibodies display disulfide-mediated structural isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Structural and functional characterization of disulfide isoforms of the human IgG2 subclass

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Complement is activated by IgG hexamers assembled at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755

Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1501755